The Hart-Scott-Rodino (HSR) Act waiting period expired on May 21, 2026, satisfying a critical regulatory condition for the acquisition of Centessa Pharmaceuticals by Eli Lilly. The acquisition is structured as a court-sanctioned scheme of arrangement under the UK Companies Act of 2006. The transaction remains subject to remaining closing conditions, including shareholder approval and sanctioning by the High Court of Justice of England and Wales.